Erythroferrone Expression in Anemic Rheumatoid Arthritis Patients: Is It Disordered Iron Trafficking or Disease Activity?
DAS28
anemia of chronic disease
erythroferrone
hepcidin
iron
rheumatoid arthritis
Journal
Journal of inflammation research
ISSN: 1178-7031
Titre abrégé: J Inflamm Res
Pays: New Zealand
ID NLM: 101512684
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
07
2021
accepted:
19
08
2021
entrez:
15
9
2021
pubmed:
16
9
2021
medline:
16
9
2021
Statut:
epublish
Résumé
Erythroferrone (ERFE) is well acknowledged for its inhibitory function on hepcidin synthesis in the liver during stress erythropoiesis, thereby ensuring sufficient iron supply to bone marrow erythroblasts. Hepcidin plays an indispensable role in the pathogenesis of anemia of chronic disease (ACD). Thus, ERFE was suggested to protect against ACD in various diseases. Rheumatoid arthritis (RA) is commonly involved with ACD and high hepcidin levels, with a further increase of the latter in active states. The present study is a case-control study that aimed to determine the pattern of ERFE expression in RA patients with concomitant ACD and study its relationship with hepcidin, erythropoietin (EPO) and disease activity. Fifty-five RA patients with ACD were categorized into active and inactive RA using the disease activity score (DAS28); 15 healthy subjects were included as control subjects. ERFE was measured for patients and control subjects using quantitative real-time polymerase chain reaction, in addition to testing for CBC, ESR, CRP, iron profile parameters and hepcidin. EPO was assessed for patients of both active and inactive RA groups. ERFE and hepcidin showed the highest levels in active RA; ERFE values were similar in control subjects and inactive RA patients, while hepcidin was significantly higher in inactive RA than control subjects. Patients with high ERFE levels had higher RBC, Hct, MCV, hepcidin and EPO levels. Stepwise regression analysis has identified DAS28 and disease duration as the best predictors of ERFE values, whereas ERFE and hepcidin were independent predictors of disease activity. We introduce ERFE as a novel marker of RA activity. Although the inhibitory effect of ERFE on hepcidin is not evident, our results still indicate that ERFE may have a beneficial erythropoietic effect in the context of ACD in RA disease activity.
Identifiants
pubmed: 34522114
doi: 10.2147/JIR.S327465
pii: 327465
pmc: PMC8434928
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4445-4455Informations de copyright
© 2021 Youssef et al.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest in this work to disclose.
Références
PLoS One. 2016 Mar 15;11(3):e0151601
pubmed: 26978524
Blood. 2002 Jul 15;100(2):474-82
pubmed: 12091338
Clin Exp Rheumatol. 2008 Jul-Aug;26(4):596-603
pubmed: 18799090
Intern Med. 2009;48(6):421-6
pubmed: 19293540
Ann Rheum Dis. 2009 Jun;68(6):954-60
pubmed: 18490431
Haematologica. 2018 Apr;103(4):e141-e142
pubmed: 29419424
Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S19-28
pubmed: 16273781
Ann Rheum Dis. 1985 Sep;44(9):580-4
pubmed: 3876077
Ann Rheum Dis. 2010 Sep;69(9):1580-8
pubmed: 20699241
Blood. 2018 Oct 4;132(14):1473-1477
pubmed: 30097509
Mediators Inflamm. 2014;2014:425068
pubmed: 24799765
Eur J Intern Med. 2014 Jan;25(1):12-7
pubmed: 23988263
Nat Genet. 2014 Jul;46(7):678-84
pubmed: 24880340
Eur J Rheumatol. 2018 Dec 19;6(2):76-80
pubmed: 31365340
Ann Rheum Dis. 1996 Mar;55(3):162-8
pubmed: 8712878
Arthritis Rheum. 2010 Nov;62(11):3173-82
pubmed: 20589684
Blood. 2016 Jun 9;127(23):2809-13
pubmed: 27044621
Blood. 2019 Jan 3;133(1):40-50
pubmed: 30401705
Diabetologia. 2019 Sep;62(9):1523-1528
pubmed: 31263909
Blood. 2001 Oct 15;98(8):2345-51
pubmed: 11588029
Am J Hematol. 2017 Nov;92(11):1204-1213
pubmed: 28815688
J Diabetes Res. 2015;2015:359159
pubmed: 26075283
Front Physiol. 2019 Oct 09;10:1294
pubmed: 31649559
Int J Mol Sci. 2021 Mar 05;22(5):
pubmed: 33807959
Hemasphere. 2018 Mar 28;2(2):e35
pubmed: 31723763
J Endocrinol. 2010 Apr;205(1):87-95
pubmed: 20061512
Blood Res. 2018 Mar;53(1):18-24
pubmed: 29662858
Anemia. 2019 Apr 1;2019:3457347
pubmed: 31057960
Sci Rep. 2020 Oct 6;10(1):16645
pubmed: 33024253
Biochemistry. 2020 Jul 28;59(29):2684-2697
pubmed: 32602701
J Biol Chem. 2012 Apr 6;287(15):11968-80
pubmed: 22351773
J Clin Endocrinol Metab. 2018 Jan 1;103(1):139-147
pubmed: 29161407
Hemoglobin. 2020 Jul;44(4):272-277
pubmed: 32718192
J Clin Med. 2019 Apr 16;8(4):
pubmed: 30995819
N Engl J Med. 2005 Mar 10;352(10):1011-23
pubmed: 15758012
Am Heart J. 2000 Jul;140(1):98-104
pubmed: 10874269
Blood. 2014 Oct 16;124(16):2569-74
pubmed: 25193872
Ann Clin Biochem. 2020 Sep;57(5):360-364
pubmed: 32588645
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Ann Hematol. 2020 Jan;99(1):31-39
pubmed: 31834456
J Endocrinol. 2015 May;225(2):77-88
pubmed: 25767056
Br J Haematol. 2011 Aug;154(3):289-300
pubmed: 21615381
J Clin Invest. 2004 May;113(9):1271-6
pubmed: 15124018